Literature DB >> 24771230

Prediagnostic telomere length and risk of B-cell lymphoma-Results from the EPIC cohort study.

Fatemeh Saberi Hosnijeh1, Giuseppe Matullo, Alessia Russo, Simonetta Guarrera, Federica Modica, Alexandra Nieters, Kim Overvad, Per Guldberg, Anne Tjønneland, Federico Canzian, Heiner Boeing, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Giovanna Tagliabue, Rosario Tumino, Salvatore Panico, Domenico Palli, Karina Standahl Olsen, Elisabete Weiderpass, Miren Dorronsoro, Eva Ardanaz, Maria-Dolores Chirlaque, María-José Sánchez, J Ramón Quirós, Adoración Venceslá, Beatrice Melin, Ann Sofie Johansson, Peter Nilsson, Signe Borgquist, Petra H Peeters, N Charlotte Onland-Moret, H B Bueno-de-Mesquita, Ruth C Travis, Kay-Tee Khaw, Nick Wareham, Paul Brennan, Pietro Ferrari, Marc J Gunter, Paolo Vineis, Roel Vermeulen.   

Abstract

Recent epidemiological investigations have reported on the association between telomere length (TL) and a number of malignancies, including B-cell lymphoma (BCL). The reported results for BCLs are however inconsistent. We carried out a nested case-control study to determine whether TL is associated with future risk of BCL. Using quantitative polymerase chain reaction, the relative TL (i.e. the ratio of telomere repeat copy number to single gene copy number) was measured in mononuclear cell DNA of prediagnostic peripheral blood samples of 464 lymphoma cases and 464 matched controls (median time between blood collection and diagnosis, 4.6 years). Conditional logistic regression was used to analyze the association between TL and the risk of developing lymphoma and histologic subtypes. TL was significantly longer in cases compared to controls (p = 0.01). Multivariable models showed a significantly increased risk of BCL [odds ratio (OR) = 1.66, 1.80 and 3.20 for quartiles 2-4, respectively, p-trend = 0.001], diffuse large B-cell lymphoma (DLBCL) (OR = 1.20, 2.48 and 2.36 for quartiles 2-4, respectively, p-trend = 0.03) and follicular lymphoma (FL) (OR = 1.39, 1.90 and 2.69 for quartiles 2-4, respectively, p-trend = 0.02) with increasing TL. This study suggests an association between longer leucocyte TL and increased risk of BCL which was most pronounced for DLBCL and FL.
© 2014 UICC.

Entities:  

Keywords:  NHL; lymphoma; prospective study; telomeres

Mesh:

Substances:

Year:  2014        PMID: 24771230     DOI: 10.1002/ijc.28934

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients.

Authors:  Junfeng Xu; Wen-Shin Chang; Chia-Wen Tsai; Da-Tian Bau; Yifan Xu; John W Davis; Timothy C Thompson; Christopher J Logothetis; Jian Gu
Journal:  EBioMedicine       Date:  2020-01-22       Impact factor: 8.143

2.  Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients.

Authors:  Shaogui Wan; Hie-Won Hann; Zhong Ye; Richard S Hann; Yinzhi Lai; Chun Wang; Ling Li; Ronald E Myers; Bingshan Li; Jinliang Xing; Hushan Yang
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

3.  Parental Age at Birth and Risk of Hematological Malignancies in Older Adults.

Authors:  Lauren R Teras; Mia M Gaudet; Jennifer L Blase; Susan M Gapstur
Journal:  Am J Epidemiol       Date:  2015-05-11       Impact factor: 4.897

Review 4.  Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Authors:  Oluwatobi O Ozoya; Julio Chavez; Lubomir Sokol; Samir Dalia
Journal:  Ann Transl Med       Date:  2017-02

5.  A Prospective Study Investigating Prediagnostic Leukocyte Telomere Length and Risk of Developing Rheumatoid Arthritis in Women.

Authors:  Jennifer Prescott; Elizabeth W Karlson; Esther H Orr; Robert Y L Zee; Immaculata De Vivo; Karen H Costenbader
Journal:  J Rheumatol       Date:  2016-01-15       Impact factor: 4.666

6.  Serum polychlorinated biphenyls and leukocyte telomere length in a highly-exposed population: The Anniston Community Health Survey.

Authors:  Catherine L Callahan; Marian Pavuk; Linda S Birnbaum; Xuefeng Ren; James R Olson; Matthew R Bonner
Journal:  Environ Int       Date:  2017-09-05       Impact factor: 9.621

Review 7.  Telomere length and common disease: study design and analytical challenges.

Authors:  Jennifer H Barrett; Mark M Iles; Alison M Dunning; Karen A Pooley
Journal:  Hum Genet       Date:  2015-05-19       Impact factor: 4.132

8.  The association between telomere length and cancer risk in population studies.

Authors:  Xun Zhu; Wei Han; Wenjie Xue; Yuxia Zou; Cuiwei Xie; Jiangbo Du; Guangfu Jin
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

9.  Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia.

Authors:  Juhi Ojha; Veryan Codd; Christopher P Nelson; Nilesh J Samani; Ivan V Smirnov; Nils R Madsen; Helen M Hansen; Adam J de Smith; Paige M Bracci; John K Wiencke; Margaret R Wrensch; Joseph L Wiemels; Kyle M Walsh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-13       Impact factor: 4.254

10.  Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes.

Authors:  Mitchell J Machiela; Qing Lan; Susan L Slager; Roel C H Vermeulen; Lauren R Teras; Nicola J Camp; James R Cerhan; John J Spinelli; Sophia S Wang; Alexandra Nieters; Joseph Vijai; Meredith Yeager; Zhaoming Wang; Hervé Ghesquières; James McKay; Lucia Conde; Paul I W de Bakker; David G Cox; Laurie Burdett; Alain Monnereau; Christopher R Flowers; Anneclaire J De Roos; Angela R Brooks-Wilson; Graham G Giles; Mads Melbye; Jian Gu; Rebecca D Jackson; Eleanor Kane; Mark P Purdue; Claire M Vajdic; Demetrius Albanes; Rachel S Kelly; Mariagrazia Zucca; Kimberly A Bertrand; Anne Zeleniuch-Jacquotte; Charles Lawrence; Amy Hutchinson; Degui Zhi; Thomas M Habermann; Brian K Link; Anne J Novak; Ahmet Dogan; Yan W Asmann; Mark Liebow; Carrie A Thompson; Stephen M Ansell; Thomas E Witzig; Hervé Tilly; Corinne Haioun; Thierry J Molina; Henrik Hjalgrim; Bengt Glimelius; Hans-Olov Adami; Göran Roos; Paige M Bracci; Jacques Riby; Martyn T Smith; Elizabeth A Holly; Wendy Cozen; Patricia Hartge; Lindsay M Morton; Richard K Severson; Lesley F Tinker; Kari E North; Nikolaus Becker; Yolanda Benavente; Paolo Boffetta; Paul Brennan; Lenka Foretova; Marc Maynadie; Anthony Staines; Tracy Lightfoot; Simon Crouch; Alex Smith; Eve Roman; W Ryan Diver; Kenneth Offit; Andrew Zelenetz; Robert J Klein; Danylo J Villano; Tongzhang Zheng; Yawei Zhang; Theodore R Holford; Jenny Turner; Melissa C Southey; Jacqueline Clavel; Jarmo Virtamo; Stephanie Weinstein; Elio Riboli; Paolo Vineis; Rudolph Kaaks; Heiner Boeing; Anne Tjønneland; Emanuele Angelucci; Simonetta Di Lollo; Marco Rais; Immaculata De Vivo; Edward Giovannucci; Peter Kraft; Jinyan Huang; Baoshan Ma; Yuanqing Ye; Brian C H Chiu; Liming Liang; Ju-Hyun Park; Charles C Chung; Dennis D Weisenburger; Joseph F Fraumeni; Gilles Salles; Martha Glenn; Lisa Cannon-Albright; Karen Curtin; Xifeng Wu; Karin E Smedby; Silvia de Sanjose; Christine F Skibola; Sonja I Berndt; Brenda M Birmann; Stephen J Chanock; Nathaniel Rothman
Journal:  Hum Mol Genet       Date:  2016-02-09       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.